Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Predictive Biomarker Analysis and Model Construction of Tislelizumab Combined With Chemotherapy for Perioperative Treatment of G/GEJ Adenocarcinoma: A Single-center, Observational Study

NCT05508399 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT05508399
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05508399 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Predictive Biomarker Analysis and Model Construction of Tislelizumab Combined With Chemotherapy for Perioperative Treatment of G/GEJ Adenocarcinoma: A Single-center, Observational Study
Lead sponsor
Xijing Hospital
Phase
Observational
Overall status
Completed
Start date
July 18, 2022
Completion date
October 10, 2025
Enrollment
28 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced gastric adenocarcinoma, pd-1